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A B S T R A C T
The role of antibiotics in the epidemiology of vancomycin-resistant Enterococcus (VRE) has been studied
extensively, but controversies remain as to which, and to what extent, antibiotics facilitate the emergence
and dissemination of VRE in hospitals. Aggregate data on the use of several antibiotic classes in terms of
defined daily doses (DDD) per 100 patient-days (PD), and VRE incidence rates in terms of clinical
isolates per 1000 PD, were evaluated during a 7-year period at a tertiary-care hospital. Time-series
analysis (autoregressive integrated moving average (ARIMA) and transfer function models) was used to
quantify the temporal effect of antibiotic use on VRE incidence and estimate effect-delays. The incidence
rate of VRE observed in a specific bimester was found to be a function of its value during the preceding
bimester and of prior changes in the volume of use of four antibiotic classes. In particular, an increase of
one DDD ⁄ 100 PD in the use of glycopeptides, fluoroquinolones, extended-spectrum cephalosporins and
b-lactam–b-lactamase inhibitor combinations resulted, independently, in average changes of +0.024,
+0.015, + 0.020 and )0.010 isolates per 1000 PD in the incidence of VRE, with average delays of 2, 4, 2
and 6 months, respectively, which explained 56% of the observed variation in VRE rates over time.
Efforts to reduce VRE cross-transmission should be supplemented by targeted antibiotic control policies.
The use of glycopeptides, broad-spectrum cephalosporins and fluoroquinolones in high amounts should
be the targets of such policies. Penicillin–b-lactamase inhibitor combinations might be suitable
substitutes for extended-spectrum cephalosporins.
Keywords Antibiotic use, ARIMA, time series, transfer function model, vancomycin-resistant Enterococcus
Original Submission: 4 November 2007; Revised Submission: 7 March 2008; Accepted: 15 March 2008
Edited by E. Tacconelli
Clin Microbiol Infect 2008; 14: 747–754
I N T R O D U C T I O N
Vancomycin-resistant Enterococcus (VRE) has
become established as a significant nosocomial
pathogen since it was first reported 20 years ago
[1]. A large body of research on the epidemiology
of VRE has indicated that the appearance and
dissemination of VRE within hospitals are depen-
dent on multiple factors related to exposure to
VRE reservoirs, host factors predisposing the
patient to colonization or infection with VRE,
and exposure to antibiotics [1–3].
The role of antibiotics in the epidemiology of
VRE has been studied extensively, but controver-
sies remain as to which, and to what extent,
antibiotics facilitate the emergence and spread of
VRE [1–4]. Increased risk of colonization or
infection with VRE has been most frequently,
but inconsistently, associated with exposure to
extended-spectrum cephalosporins, fluoroquino-
lones, glycopeptides and anti-anaerobic agents
such as metronidazole, clindamycin and imipe-
nem [4]. In contrast, some evidence suggests that
the use of b-lactam–b-lactamase-inhibitor combi-
nations may be protective against VRE dissemi-
nation [4,5]. Moreover, antibiotic formulary
interventions, most frequently employing
restriction of vancomycin and broad-spectrum
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cephalosporins, have shown variable effects in
controlling VRE [4,6].
In the 700-bed, tertiary-care University Hospi-
tal of Heraklion, we had the opportunity to
observe the evolution of VRE since its initial
emergence in 2000 [7]. Over the following years,
VRE became endemic in the hospital despite
infection control efforts [8]. In parallel, a signifi-
cant, frequently excessive, increase in the use of
antimicrobials was noticed in the hospital, includ-
ing antibiotics commonly implicated in facilitat-
ing VRE colonization or infection [9].
The objective of this study was to investigate
and quantify the temporal relationship between
the use of several antibiotic classes and VRE
incidence, using time-series analysis of hospital-
wide surveillance data obtained over a 7-year
period. The ultimate goal was to stimulate
evidence-based antibiotic control interventions,
targeted to those antibiotics that facilitate the
emergence and spread of VRE in the hospital
setting.
M A T E R I A L S A N D M E T H O D S
Vancomycin-resistant enterococci
The number of VRE isolates from clinical cultures, excluding
Enterococcus gallinarum and E. casseliflavus, during the period
2000–2006, was obtained from the microbiology laboratory
database. Duplicate isolates, defined as those having the same
resistance pattern as those recovered from the same patient
during the same month, were excluded from analysis. Isolates
obtained from colonization screening surveys (stool speci-
mens) were also excluded [10]. The incidence density rate of
VRE was calculated as the number of VRE isolates per 1000
patient-days (PD), at bimonthly and yearly time intervals and
for the pool of the study period.
Antibiotic use
Antibiotics were classified according to the anatomic thera-
peutic chemical (ATC) classification system. Volume data,
obtained from the pharmacy dispensing records for the period
2000–2006, were converted into defined daily doses (DDD)
according to the 2006 version of the ATC ⁄DDD system, and
were standardized into usage density rates per 100 PD
(DDD ⁄ 100 PD) at bimonthly and yearly intervals [11]. Evalu-
ation of use was limited to antibiotic classes that have been
commonly implicated as either risk factors or protective factors
for VRE occurrence [4]. Groups included in the analysis were
b-lactam–b-lactamase inhibitor combinations (ampicillin–
sulbactam, amoxycillin–clavulanate, ticarcillin–clavulanate,
and piperacillin–tazobactam), second-generation cephalospo-
rins (cefuroxime, ceforanide, cefaclor, cefamandole, and
cefoxitin), extended-spectrum cephalosporins (ceftriaxone,
ceftazidime, cefotaxime, cefixime, and cefepime), fluoroqui-
nolones (ciprofloxacin, levofloxacin, ofloxacin, moxifloxacin,
and norfloxacin), glycopeptides (vancomycin and teicoplanin),
carbapenems (imipenem and meropenem), imidazoles (met-
ronidazole and ornidazole) and lincosamides (clindamycin).
Statistical analysis
Linear trends of bimonthly antibiotic use rates were described
by the p-value and the sign of the slope coefficient in linear
regression on time. The Box and Jenkins (autoregressive
integrated moving average (ARIMA)) modelling approach
was employed to analyze the temporal behaviour of bimonthly
VRE rates, based on its previous values, trends and abrupt
changes in the recent past. Linear transfer function (LTF)
modelling was used to quantify the dynamic relationship
between the use of several antibiotic groups and VRE inci-
dence, taking into account possible delays of effects. These
approaches have been used previously to study relationships
between antimicrobial use and resistance [12–15], and have
been described in detail by Monnet et al. [16].
The optimum LTF model was developed as a polynomial
distributed lag regression model, through the use of the
‘general-to-specific’ approach [13]. In particular, all series of
bimonthly antibiotic use rates were included in an initial
model. First-order differencing was used for all input series to
obtain stationarity, and lags of up to two time-points were
considered (up to 6-month delays, accounting for the differ-
encing). The initial model was the following:
rVRE tð Þ ¼ cþ
X
k
X2
i¼0
wkirXk t ið Þ þ eðtÞ;
where VRE(t) denotes the series of bimonthly VRE incidence
rates,  is the first-order differencing operator (e.g.
VRE(t) = VRE(t) – VRE(t – 1)), Xk(t) denotes the input series
of antibiotic use rates, and e(t) is the residual series, which can
be seen as describing the effect of all factors other than those
included in the model. The residual series was initially
approached using an autoregressive model of order 1. This
initial model was fitted to the data series to obtain estimates for
parameters c and wki. The estimation results suggested that
some parameters were zero and should be eliminated from the
model. In this way, the initial model was progressively
simplified. The simplification process involved three iterative
steps: (i) identification of a tentative model by eliminating
unnecessary lags and non-significant terms, and specification
of a tentative ARIMA model for the residuals; (ii) estimation of
the parameters of the identified model; and (iii) use of
diagnostic checks to examine model adequacy, including the
T-ratio test for the statistical significance of parameters, and
the Ljung–Box statistic to verify that residuals had no auto-
correlation pattern and corresponded to white noise. The
determination coefficient, R2, corresponding to the percentage
of the variance of the observed time series of VRE rates
explained by the model, was calculated for the LTF model and
for the ARIMA model solely on the basis of past VRE rates.
Data were analyzed using the Trends module of SPSS for
Windows, version 15.
R E S U L T S
During the study period, 113 non-duplicate, non-
screening VRE strains were isolated, including 80
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(71%) E. faecium and 33 (29%) E. faecalis strains,
from patients hospitalized in 21 ⁄ 32 hospital
wards. The most common clinical specimens
cultured were urine (36%), blood (19%) and pus
(10%). Various other samples (cerebrospinal
fluid, peritoneal fluid, pleural fluid, soft tissue
sample, etc.) accounted for less than 5% each.
Among the vancomycin-resistant E. faecium
isolates, 74 (93%) had the VanA phenotype and
six (7%) the VanB phenotype of resistance.
All E. faecalis isolates had the VanA resistance
phenotype.
The overall incidence density of VRE, pooled
over the study period, was 0.090 isolates per
1000 PD, varying from 0.044 in surgical wards
and 0.067 in medical wards, to 0.199 in haemato-
oncology wards and 0.227 in intensive-care units.
Increasing annual rates of VRE were observed in
all patient-care areas throughout the study period
(Fig. 1).
The hospital-wide antimicrobial use rate,
pooled over the study period, was 105.7 DDD ⁄
100 PD. A significant trend towards increasing
overall use was observed from the beginning to
the end of the study period (p <0.001), with use in
2006 being 18.5% higher than in 2000. The indi-
vidual classes studied accounted for 70.5% of total
antibiotic use (Fig. 2). Cephalosporins comprised
the most widely used group (23.7% of total
use; pooled rate, 25.0 DDD ⁄ 100 PD), and use
throughout the study period was constant
(p 0.572). Second in rank of use was the group of
b-lactam–b-lactamase inhibitor combinations,
which accounted for 18.0% of total antibiotic use
(pooled rate, 19.0 DDD ⁄ 100 PD) and showed an
increasing linear trend during the study period
(p <0.001), with an annual average increase of
0.53 DDD ⁄ 100 PD. Fluoroquinolones (13.3% of
total use; pooled rate, 14.0 DDD ⁄ 100 PD) showed
a significantly increasing trend (p <0.001), with
a marked annual average increase of 1.89 DDD ⁄
100 PD. Glycopeptides accounted for 4.5% of
total antibiotic use (pooled rate, 4.8 DDD ⁄ 100 PD)
and their use significantly increased during the
study period (p 0.005), with an annual average
increase of 0.17 DDD ⁄ 100 PD. Carbapenems
(3.9% of total use; pooled rate, 4.1 DDD ⁄ 100 PD)
also increased in use (p <0.001), with an annual
average increase of 0.54 DDD ⁄ 100 PD. The use of
imidazoles accounted for 3.6% of total antibiotic
use (pooled rate, 3.8 DDD ⁄ 100 PD), and had
an increasing linear trend (annual average
increase, 0.31 DDD ⁄ 100 PD; p 0.007). Clindamy-
cin accounted for 3.5% of total antibiotic use
(pooled rate, 3.7 DDD ⁄ 100 PD), and showed a
decreasing linear trend during the study period
(annual average decrease, 0.07 DDD ⁄ 100 PD;
p 0.001).
Using the Box–Jenkins method, an ARIMA
model was developed for the time series of
bimonthly VRE incidence rates. The series became
stationary after first-order differencing. The
Fig. 1. Annual incidence rates of vancomycin-resistant
enterococci (VRE) (number of VanA and VanB isolates
per 1000 patient-days) for different patient-care areas,
University Hospital of Heraklion, 2000–2006.
Fig. 2. Annual rates of hospital-wide use of main antimi-
crobial groups, measured in defined daily doses (DDD) per
100 patient-days (PD), University Hospital of Heraklion,
2000–2006.
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model was of the form ARIMA (0, 1, 1), having
only one significant first-order moving average
term. Table 1 (part A) presents the univariate
analysis model, which can also be represented by
the equation VRE(t) = VRE(t – 1) + e(t) – 0.667
e(t – 1), where the term VRE(t) denotes the
incidence of vancomycin-resistant enterococci at
time t (measured in 2-month intervals), and the
term e(t) denotes a random error at time t
describing the effects of all factors other than
VRE(t – 1) on VRE(t). According to this model,
the incidence of VRE at time t is related to the
same incidence observed at the previous time-
point t – 1, plus a moving average term repre-
senting disturbances or abrupt changes of VRE
rates. The determination coefficient (R2) was 0.49,
indicating that the model explained 49% of the
variations in VRE rates over time.
Following the LTF modelling approach, the
series of bimonthly antibiotic use rates were
introduced into the model. This resulted in the
multivariate model shown in Table 1 (part B),
having the series of bimonthly usage rates of four
antibiotic classes as significant predictors. This
model can be represented by the equation
VRE(t) = VRE(t – 1) + 0.024(XA(t) – XA(t – 1)) +
0.015(MA(t – 1) – MA(t – 2)) + 0.020(DD(t) –
DD(t – 1)) – 0.010(CR(t – 2) – CR(t – 3)) + e(t),
where the incidence rate of VRE observed in a
specific bimester is a function of the same inci-
dence observed during the preceding bimester
and of the change that occurred in the use
of glycopeptides (XA), fluoroquinolones (MA),
extended-spectrum cephalosporins (DD) and
b-lactamase inhibitors (CR), plus an error e(t)
representing the effects of all factors other than
those included in the model.
According to the LTF model, the use of
glycopeptides had a positive relationship with
the incidence of VRE: an increase of
1 DDD ⁄ 100 PD of glycopeptide use results, with
an average delay of 2 months, in an average
increase of 0.024 VRE isolates per 1000 PD, after
taking into account the current level of VRE
incidence and the changes in the use of the
other antibiotic classes. Similar interpretations
hold for the other classes of antibiotics in the
model. An increase of 1 DDD ⁄ 100 PD in the use
of extended-spectrum cephalosporins and fluor-
oquinolones results, independently, in average
increases of 0.020 and 0.015 in the incidence of
VRE, with average delays of 2 and 4 months,
respectively. In contrast, b-lactam–b-lactamase
inhibitor combinations showed an inverse rela-
tionship with VRE incidence: an increase of
1 DDD ⁄ 100 PD in their use results, with an
average delay of 6 months, in an average
decrease of 0.010 in the incidence of VRE. Other
antimicrobial groups, including second-genera-
tion cephalosporins, carbapenems, imidazoles
and lincosamides, did not enter the model as
significant predictors.
The determination coefficient of the LTF model
was 0.56, implying that the model explained 56%
of the observed variation in the VRE rates over
time. In Fig. 3, the actual VRE rates observed
during the study period have been plotted against
the rates predicted by the LTF model, showing
that the model mimics very well the actual
evolution of VRE rates over time.
Table 1. Autoregressive integrated moving average (ARIMA) and linear transfer function (LTF) models used to estimate
the dynamic relationship between the hospital-wide incidence of vancomycin-resistant Enterococcus (VRE) and antibiotic
use, University Hospital of Heraklion, 2000–2006
Terma Delayb
Parameter estimation
Ljung–Box
Statisticd
R2 coefficientValue (SE)c T-ratio p Value p
A. ARIMA model for the incidence of VRE
Moving average 1 +0.667 (0.121) 5.52 <0.001 20.5 0.251 0.49
B. LTF model for VRE incidence,
accounting for antibiotic use
Glycopeptide use 1 +0.024 (0.009) 2.80 0.008 18.5 0.424 0.56
Fluoroquinolone use 2 +0.015 (0.005) 2.74 0.010
Third- and fourth-generation cephalosporins 1 +0.020 (0.009) 2.22 0.033
Combinations of penicillins with BLI 3 )0.010 (0.005) )2.10 0.043
SE, standard error; BLI, b-lactamase inhibitors.
aFirst-order differencing was used for all time series involved in the models.
bDelay before effect is observed (measured in 2-month intervals), accounting for the order of series differencing.
cSize and direction of the effect.
dDiagnostic check for model residuals. A significant value implies that there is a structure in the observed series that is not accounted for by the model.
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D I S C U S S I O N
Antibiotic use has been ascribed a crucial role in
the nosocomial epidemiology of VRE. Antibiotic
exposure may select for VRE in colonized
patients, may decrease resistance against coloni-
zation of the gastrointestinal tract of patients
previously free of VRE, and may facilitate VRE
transmission by causing stool incontinence, thus
increasing the risk of environmental contamina-
tion [17,18].
However, findings implicating specific antibi-
otics in the emergence and spread of VRE and
corresponding effect estimates have been incon-
sistent across published studies [4]. For instance,
the effect of vancomycin use has been controver-
sial. In a meta-analysis of patient-level studies,
Carmeli et al. [19] concluded that the association
between vancomycin treatment and the risk of
VRE colonization or infection that has been
reported in the literature may be due to inappro-
priate control group selection and confounding
by time at risk, and noted that studies that
accounted for these factors did not reveal signif-
icant associations. However, most of these studies
did not examine the interactions of several anti-
biotic classes, and used binary (yes ⁄no) antibiotic
exposure variables during the limited risk period
of hospital stay, and thus did not account for dose
dependencies and time effects [4]. Moreover, only
a few studies assessed the influence of contact
patterns with VRE carriers or overall colonization
pressure [20]; therefore, factors central to VRE
transmission have not been taken into account in
reported associations [4].
Population-based studies have also been em-
ployed to investigate the role of vancomycin use
in the epidemiology of VRE at the level of a ward
or hospital. A large study conducted at 126 US
intensive-care units showed that vancomycin
exposure was the most significant modifiable risk
factor for VRE colonization [10]. Yet, in a recent
systematic review focusing on population-level
associations, it was not possible to conclusively
determine a potential role for reductions in
vancomycin use in controlling VRE [6].
Aside from confounding and misclassification
biases that may explain divergence in individual-
level and ecological-level associations [21],
another possible explanation involves the viola-
tion of the assumptions of independence and
dynamic linearity required by classical statistical
techniques [22]. Cross-transmission of VRE may
create non-linear population dynamics, as expo-
sure to antibiotics may increase the risk of
acquisition, not only for the exposed individual,
but also for close contacts [21]. When there is
dependence of outcome among individuals, nei-
ther regression coefficients from ecological stud-
ies nor risk measures from patient-level studies
can accurately reflect how much change in VRE
incidence can be expected from a given change in
antibiotic exposure [22]. Classical regression tech-
niques cannot account for the population dynam-
ics of the relationship, i.e. the effect of past VRE
rates on current rates and the necessary delay
before a change of antibiotic use affects VRE
incidence [12].
In this study, time-series analysis was used to
create a model of the incidence of VRE over time,
as a function of its retrospective behaviour and
prior usage rates of several antibiotic classes.
Unlike usual statistical methods, this approach
takes into account the correlation between
consecutive observations in order to describe
concomitant variations, i.e. changes in antibiotic
use followed by changes in VRE rates [16]. Using
this approach, it was possible to quantify the
relationship between variations in use of glyco-
peptides and subsequent variations in VRE rates,
after controlling for past levels of VRE incidence
and use of other antibiotics. This model showed
that an increase of 1 DDD ⁄ 100 PD of glycopep-
tide use results, independently, in a subsequent
average increase of 0.024 VRE isolates per
0.35 Observed VRE incidence rates
VRE incidence rates predicted by LTF models
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Fig. 3. Observed bimonthly incidence of vancomycin-
resistant enterococci (VRE) as compared to incidence
predicted by the linear transfer function model (LTF),
University Hospital of Heraklion, 2000–2006.
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1000 PD. Therefore, it suggests that glycopeptide
use contributes to VRE occurrence at the popula-
tion level and should be a target of policies
aiming at controlling VRE, as recommended by
current guidelines [23].
This analysis also demonstrated a positive
temporal relationship between VRE rates and
the use of extended-spectrum cephalosporins and
fluoroquinolones. In particular, increases of
1 DDD ⁄ 100 PD in the use of extended-spectrum
cephalosporins and fluoroquinolones resulted,
independently, in subsequent average increases
of 0.020 and 0.015 in VRE incidence, respectively.
These findings are consistent with a meta-analysis
of patient-level studies, which showed significant
associations with the risk of VRE colonization or
infection for broad-spectrum cephalosporins (OR,
3.44; p <0.001) and fluoroquinolones (OR, 2.33;
p <0.001) [4].
Evidence of a negative effect against the spread
of VRE for b-lactam–b-lactamase inhibitor combi-
nations has been reported in patient-level studies
[4,5]. Moreover, formulary substitution of b-lac-
tam–b-lactamase inhibitors for broad-spectrum
cephalosporins has been associated with reduc-
tions in VRE rates [24–26]. This model produced
results in agreement with these observations, by
showing an inverse temporal correlation between
b-lactam–b-lactamase combinations and VRE
rates.
A significant increase in overall antibiotic use
was noted during the study period (18.5%),
including the groups of antibiotics that were
implicated in the analysis as independent predic-
tors of VRE incidence. The results reveal up to
three-fold higher rates of antibiotic use than those
reported by individual hospitals or multicentre
studies in other European countries [9,11], indi-
cating that there was considerable inappropriate
use of antibiotics in the study setting. The analysis
suggested that restricting the use of glycopep-
tides, broad-spectrum cephalosporins and fluor-
oquinolones may help to control the increasing
incidence of VRE. This is, however, a difficult and
complex task in today’s era of multidrug resis-
tance. In the study setting, the proportion of
enterococci exhibiting acquired resistance to
vancomycin remains less than 10% [7,8], suggest-
ing that a shift towards routine use of linezolid or
daptomycin, and decreased use of vancomycin,
would not be recommended. In contrast, efforts
should be focused on diminishing unnecessary
use and ensuring prudent use of vancomycin by
harmonizing current practices with prevailing
guidelines [23]. Moreover, any effort to limit the
use of fluoroquinolones and extended-spectrum
cephalosporins should be made with care, be-
cause it may lead to an increase in the use of other
groups of antibiotics (e.g. carbapenems), with a
resulting selection of different resistant organ-
isms, perhaps more virulent than VRE. These
results suggested that b-lactam–inhibitor combi-
nations might be suitable substitutes for broad-
spectrum cephalosporins in order to control VRE,
but it is also important that current practices in
the use of cephalosporins are examined thor-
oughly to determine targets for limiting unneces-
sary or inappropriate use.
Using time-series modelling, it was also possi-
ble to estimate the time-lags between variations in
antibiotic use and subsequent variations in VRE
incidence. Effect-delays ranged between 2 and
4 months for the three antibiotic groups found to
be positively correlated with VRE rates, whereas
the effect-delay was longer (6 months) for
b-lactam–b-lactamase inhibitors, which exhibited
a negative relationship with VRE rates. These
findings are in line with the predictions of
mathematical models concerning the effects of
various patterns of antibiotic treatment at the
population level, which have suggested that the
spread of resistance due to antibiotic use will be
faster than its decline when selection pressure is
removed [27].
Past levels of VRE incidence are the main force
driving current VRE rates according to the study
model, and by itself, the retrospective behaviour
of VRE incidence explained 49% of the variation
in its values over time. This reflects the impor-
tance of colonization pressure in the hospital [20],
and emphasizes that efforts to reduce cross-
transmission are the cornerstone of any interven-
tion to control VRE [28]. However, it has been
noted that attempts to prevent or reduce VRE
occurrence by interventions in infection control
and antimicrobial use as separate entities may be
too simplistic. In a mathematical model describ-
ing the population-level relationship between
antibiotic use and VRE, Austin et al. [29] found
infection control measures to be closely linked
with control of antibiotic use, and suggested that
the impact of infection control efforts may be
negated by inappropriate antibiotic use. This
analysis supports these arguments, because the
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introduction of antibiotic use rates into the model
increased the proportion of the variance in VRE
rates explained by the model to 56%.
The remaining 44% of the variation in VRE
rates can be attributed to other factors, including
variations in infection control measures, cross-
transmission frequency and susceptibility of the
patient population. Therefore, the confounding
effect of these factors on the relationships
observed in this study is unknown. Infection
control measures, including prompt detection and
reporting of VRE by the microbiology laboratory,
periodically performed prevalence surveys in
high-risk units to detect VRE-colonized patients,
isolation precautions for colonized patients and
education of hospital staff regarding the problem
of vancomycin resistance, have been undertaken
in our hospital since VRE first emerged [7], but
data regarding the degree of compliance with
these efforts over time were not recorded. Pre-
sumably, if longitudinal data on factors such as
compliance rates for hand washing and glove use,
surrogates for hospital hygiene (e.g. volumes of
medicated soaps and alcoholic hand rubs) or
indicators of workload and overcrowding were
available, they could be included in the model
and could possibly increase the proportion of the
variance in VRE rates explained by the model.
Despite these limitations, the time-series analysis
of hospital-wide surveillance data from the hos-
pital pharmacy and clinical microbiology labora-
tory allowed us to quantify a temporal effect of
the use of several antibiotic classes on the inci-
dence of VRE, which in turn provided targets for
antibiotic control interventions.
In conclusion, this study has illustrated that
traditional infection control efforts to reduce
VRE cross-transmission should be supplemented
by targeted antibiotic control policies. Use of
glycopeptides, broad-spectrum cephalosporins
and fluoroquinolones in high amounts should
be the targets of such policies. Penicillin–
b-lactamase inhibitor combinations might be
suitable substitutes for extended-spectrum ceph-
alosporins.
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